scandinavian prostate cancer group scandinavian prostate cancer group the scandinavian prostate cancer group (spcg) is a group of scientific researchers who have conducted a series of clinical trials of treatments for prostate cancer. the group was founded in 1981 and the first study, spcg-1, began in 1984. clinical trials the studies conducted by the spcg include the following: spcg-1 – estramustine phosphate versus diethylstilbestrol for high-risk advanced prostate cancer spcg-2 – orchiectomy plus cyproterone acetate versus placebo for metastatic prostate cancer spcg-3 – cancelled spcg-4 – radical prostatectomy versus watchful waiting for localized prostate cancer spcg-5 – polyestradiol phosphate versus triptorelin or orchiectomy plus flutamide for advanced prostate cancer spcg-6 – bicalutamide monotherapy versus standard care (watchful waiting) for localized prostate cancer spcg-7 – endocrine therapy with versus without radiotherapy for locally advanced or aggressive localized prostate cancer spcg-8 – cancelled spcg-9 – cancelled spcg-10 – cancelled spcg-11 (zometa european study ) – zoledronic acid with standard prostate cancer therapy versus standard prostate cancer therapy alone for prevention of bone metastases in high-risk localized prostate cancer spcg-12 – docetaxel versus surveillance after radical prostatectomy without androgen deprivation therapy for high-risk localized prostate cancer spcg-13 – docetaxel versus surveillance after radical prostatectomy with androgen deprivation therapy for high-risk localized prostate cancer spcg-14 – docetaxel versus bicalutamide for prostate-specific antigen recurrence after radical prostatectomy or radiotherapy for localized prostate cancer spcg-15 – radical prostatectomy versus radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer the spcg-6 study was also known as trial 25 of the early prostate cancer (epc) clinical trial programme. other work the spcg also published a 1997 literature review on combined androgen blockade for advanced prostate cancer.